CalcMyPeptide
Growth HormoneAlso known as: GHRL, Lenomorelin, Growth hormone-releasing peptide

Ghrelin

Ghrelin is the endogenous 28-amino-acid "hunger hormone" secreted directly by gastric oxyntic cells. As the ultimate, natural biological ligand for the Growth Hormone Secretagogue Receptor (GHS-R1a), exogenous Ghrelin is essentially the blueprint from which all synthetic GHRPs (like Ipamorelin or GHRP-6) are derived. In clinical research, it is utilized to rapidly reverse severe cancer-induced cachexia, forcefully restart motility in paralyzed gastroparesis, and trigger massive systemic GH pulses.

Reviewed by CalcMyPeptide Editorial Team
Last updated: April 2026Evidence: Moderate1 peer-reviewed citation

Quick Stats

Half-LifeShort (~10-15 minutes)
Dose Range1-5 mcg/kg IV (research)
FrequencyPer study protocol
Vial Sizes5 mg
BioavailabilityInjection (endogenous peptide)
Year Developed1999

Scientific Data

Molecular Formula
C149H249N47O42 (Acyl-Ghrelin)
Molecular Weight
3370.9 g/mol
CAS Number
PubChem ID

Mechanism of Action

Ghrelin (the "hunger hormone") is a 28-amino-acid endogenous peptide produced primarily by endocrine cells in the stomach fundus. It requires octanoylation at its 3rd serine residue to become biologically active (acyl-ghrelin).

It works by binding the growth hormone secretagogue receptor 1a (GHS-R1a) in the hypothalamus, triggering two dramatic effects: profound appetite stimulation (orexigenic effect) and potent growth hormone release from the pituitary. Because the actual ghrelin peptide is highly unstable and difficult to synthesize with its required lipid modification, synthetic GHRPs (like GHRP-6, GHRP-2, Ipamorelin) or non-peptides (Macimorelin) are used instead to stimulate the ghrelin receptor therapeutically.

Source: PMID: 10604470

Background & History

Ghrelin was discovered in 1999 by Masayasu Kojima and colleagues in rat stomach. It was the first known endogenous ligand for the growth hormone secretagogue receptor (GHS-R1a), explaining how synthetic secretagogues like GHRP-6 worked. Ghrelin is now recognized as a key regulator of energy homeostasis, connecting gut-brain signaling for appetite, metabolism, and growth hormone release. Its role in cachexia (cancer-related wasting) has driven clinical trials.

Research Use Cases

  • Cancer cachexia research
  • Gastroparesis
  • GH deficiency research
  • Anorexia nervosa research
  • Post-surgical ileus

Dosing Protocol

Typical Dose1-5 mcg/kg IV (research)
FrequencyPer study protocol
Half-Life0.5 hours
Common Vial Sizes5 mg

Dosing Protocols

Reference Only

Dose
N/A
Frequency
N/A
Note: Native ghrelin is rarely used exogenously due to instability. Synthetic secretagogues (GHRPs) or MK-677 are used to bind the ghrelin receptor.

Body-Weight Dosing Reference

Estimated doses extrapolated from the published research range of 70350 mcg/day (referenced to 70 kg / 154 lb). These are approximations — consult a qualified healthcare provider for personalised guidance.

WeightLowTargetHigh
120 lb(54 kg)54 mcg162 mcg270 mcg
140 lb(63 kg)63 mcg189 mcg315 mcg
160 lb(73 kg)73 mcg219 mcg365 mcg
180 lb(82 kg)82 mcg246 mcg410 mcg
200 lb(91 kg)91 mcg273 mcg455 mcg
220 lb(100 kg)100 mcg300 mcg500 mcg
250 lb(113 kg)113 mcg339 mcg565 mcg

💉 For exact syringe units based on your vial concentration, use the Ghrelin Reconstitution Calculator →

Administration

Route
Produced endogenously by the stomach
Timing
Rises during fasting; drops after eating.
Fasting Required?
Yes — inject on an empty stomach

Expected Timeline

Immediate
Endogenous ghrelin surges prior to meals, triggering intense hunger and GH pulses.

Who Is It For?

Endogenous Marker

Moderate

Important mechanism for hunger and GH release, targeted by many other pharmacological peptides.

Reconstitution Example

Vial
5 mg
Water
2 mL
Concentration
2.5 mg/mL
Per Unit (100u syringe)
25 mcg
Dose of 70 mcg = 2.8 units on a 100-unit insulin syringe

Safety & Considerations

Endogenous hormone. High ghrelin states (Prader-Willi syndrome) cause insatiable hunger. Modulated extensively by fasting, sleep, and medical peptides.

Regulatory & Legal Status

FDA Status (US)
Research Only
WADA Status (2026)
Not Listed

Not currently on the WADA 2026 Prohibited List. Policies may change — verify before competition.

Classification

Research Chemical

US Compounding: Not eligible / not available

⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.

Interactions & Contraindications

May increase appetite and food intake. Can cause transient hyperglycemia. Interacts with insulin and leptin signaling pathways. Ghrelin O-acyltransferase (GOAT) inhibitors are being developed as anti-obesity agents.

Synergies & Common Stacks

GHRP-2 is a synthetic ghrelin receptor agonist — ghrelin is the endogenous ligand. They activate the same receptor but ghrelin has additional metabolic effects.

MK-677 is a non-peptide oral ghrelin mimetic. It provides sustained oral GHS-R1a activation that compensates for ghrelin's extremely short half-life.

Dosing Quick Reference

Ghrelin— Dosing Guide
Dose Range
1-5 mcg/kg IV (research)
Half-Life
0.5 hours
Frequency
Per study protocol
Route
Subcutaneous
5 mg vial
💧 2 mL BAC water📐 2.5 mg/mL concentration💉 25 mcg/unit (100u syringe)
Growth Hormonecalcmypeptide.com

Frequently Asked Questions

Why is native ghrelin not used as a medicine?
It requires a specific fatty acid attachment to work, making it expensive and unstable to manufacture. Instead, scientists designed synthetic peptides (like GHRP-2, Ipamorelin) that bind the same receptor but are much more stable.

References

  1. Kojima M et al. "Ghrelin is a growth-hormone-releasing acylated peptide from stomach".” Nature (1999). PMID: 10604470

Looking for a trusted source? See our recommended suppliers →

Independently tested · COA-verified · Save 10% with our exclusive code